CA3144713A1 - Pharmaeutical composition comprising ensifentrine - Google Patents
Pharmaeutical composition comprising ensifentrine Download PDFInfo
- Publication number
- CA3144713A1 CA3144713A1 CA3144713A CA3144713A CA3144713A1 CA 3144713 A1 CA3144713 A1 CA 3144713A1 CA 3144713 A CA3144713 A CA 3144713A CA 3144713 A CA3144713 A CA 3144713A CA 3144713 A1 CA3144713 A1 CA 3144713A1
- Authority
- CA
- Canada
- Prior art keywords
- dry powder
- pharmaceutical composition
- particles
- powder pharmaceutical
- ensifentrine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1911517.9A GB201911517D0 (en) | 2019-08-12 | 2019-08-12 | Pharmaceutical composition |
| GB1911517.9 | 2019-08-12 | ||
| PCT/GB2020/051914 WO2021028679A1 (en) | 2019-08-12 | 2020-08-12 | Pharmaeutical composition comprising ensifentrine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3144713A1 true CA3144713A1 (en) | 2021-02-18 |
Family
ID=67991071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3144713A Pending CA3144713A1 (en) | 2019-08-12 | 2020-08-12 | Pharmaeutical composition comprising ensifentrine |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220265549A1 (https=) |
| EP (1) | EP4013384A1 (https=) |
| JP (1) | JP7678793B2 (https=) |
| KR (1) | KR20220045214A (https=) |
| CN (1) | CN114286672A (https=) |
| AU (1) | AU2020328223B2 (https=) |
| BR (1) | BR112022002630A2 (https=) |
| CA (1) | CA3144713A1 (https=) |
| GB (1) | GB201911517D0 (https=) |
| IL (2) | IL326396A (https=) |
| MX (1) | MX2022001724A (https=) |
| MY (1) | MY208922A (https=) |
| PH (1) | PH12022550322A1 (https=) |
| WO (1) | WO2021028679A1 (https=) |
| ZA (1) | ZA202201322B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7307855B2 (ja) * | 2019-10-11 | 2023-07-12 | テレフオンアクチーボラゲット エルエム エリクソン（パブル） | 無線通信ネットワークにおける設定ダウンリンク送信および動的ダウンリンク送信をハンドリングする方法および装置 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| CN120787157A (zh) * | 2022-10-20 | 2025-10-14 | 维罗纳制药公司 | 使用恩塞芬汀治疗特发性肺纤维化 |
| KR20250087621A (ko) * | 2022-10-28 | 2025-06-16 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 이소퀴놀리논계 화합물을 포함하는 약학적 조성물 및 이의 제조 방법 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| WO2025003643A1 (en) * | 2023-06-26 | 2025-01-02 | Verona Pharma Plc | Particulate composition comprising ensifetrine |
| AU2024309346C1 (en) | 2023-06-26 | 2026-03-12 | Verona Pharma Plc | Particulate composition comprising ensifentrine |
| WO2025052119A1 (en) * | 2023-09-06 | 2025-03-13 | Verona Pharma Plc | Ensifentrine for use in treating chronic obstructive pulmonary disease (copd) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4140689B4 (de) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalationspulver und Verfahren zu ihrer Herstellung |
| DE60005493T2 (de) | 1999-03-31 | 2004-07-01 | Vernalis Ltd., Wokingham | Pyrimido[6,1-a]isochinolinonderivate |
| JO3102B1 (ar) | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| EP2968312B1 (en) * | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| MY196072A (en) | 2014-09-15 | 2023-03-13 | Verona Pharma Plc | Liquid Inhalation Formulation Comprising RPL554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2019
- 2019-08-12 GB GBGB1911517.9A patent/GB201911517D0/en not_active Ceased
-
2020
- 2020-08-12 PH PH1/2022/550322A patent/PH12022550322A1/en unknown
- 2020-08-12 MY MYPI2022000719A patent/MY208922A/en unknown
- 2020-08-12 WO PCT/GB2020/051914 patent/WO2021028679A1/en not_active Ceased
- 2020-08-12 BR BR112022002630A patent/BR112022002630A2/pt unknown
- 2020-08-12 JP JP2022508963A patent/JP7678793B2/ja active Active
- 2020-08-12 CN CN202080056792.8A patent/CN114286672A/zh active Pending
- 2020-08-12 EP EP20758285.9A patent/EP4013384A1/en active Pending
- 2020-08-12 AU AU2020328223A patent/AU2020328223B2/en active Active
- 2020-08-12 CA CA3144713A patent/CA3144713A1/en active Pending
- 2020-08-12 KR KR1020227008300A patent/KR20220045214A/ko active Pending
- 2020-08-12 IL IL326396A patent/IL326396A/en unknown
- 2020-08-12 MX MX2022001724A patent/MX2022001724A/es unknown
- 2020-08-12 US US17/632,891 patent/US20220265549A1/en active Pending
-
2022
- 2022-01-27 ZA ZA2022/01322A patent/ZA202201322B/en unknown
- 2022-02-08 IL IL290447A patent/IL290447B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220045214A (ko) | 2022-04-12 |
| ZA202201322B (en) | 2024-06-26 |
| IL290447A (en) | 2022-04-01 |
| CN114286672A (zh) | 2022-04-05 |
| BR112022002630A2 (pt) | 2022-05-03 |
| WO2021028679A1 (en) | 2021-02-18 |
| GB201911517D0 (en) | 2019-09-25 |
| WO2021028679A8 (en) | 2022-02-24 |
| AU2020328223B2 (en) | 2025-09-04 |
| JP2022550664A (ja) | 2022-12-05 |
| US20220265549A1 (en) | 2022-08-25 |
| JP7678793B2 (ja) | 2025-05-16 |
| IL290447B1 (en) | 2026-03-01 |
| IL326396A (en) | 2026-04-01 |
| PH12022550322A1 (en) | 2023-02-13 |
| MY208922A (en) | 2025-06-11 |
| MX2022001724A (es) | 2022-03-11 |
| EP4013384A1 (en) | 2022-06-22 |
| AU2020328223A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020328223B2 (en) | Pharmaeutical composition comprising ensifentrine | |
| DK1267866T4 (en) | Treatment of respiratory diseases | |
| ES2683254T3 (es) | Formulación en polvo seca que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación | |
| AU2021200503B2 (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| JP2015519394A (ja) | キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法 | |
| KR101369631B1 (ko) | 흡입용 조성물 | |
| EA036315B1 (ru) | Фармацевтическая композиция для ингаляционного применения, содержащая будесонид и формотерол, ее применение и содержащий ее набор | |
| US10786450B2 (en) | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| RU2825334C2 (ru) | Фармацевтическая композиция, содержащая энсифентрин | |
| RU2422144C2 (ru) | Применение солей тиотропия для лечения тяжелых форм персистирующей астмы | |
| EA015353B1 (ru) | Применение солей тиотропия для лечения персистирующей астмы средней тяжести | |
| CA2963445C (en) | Pharmaceutical composition containing budesonide and formoterol | |
| HK1160601A (en) | Inhalation composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250903 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250904 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20251128 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260308 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260308 |